The global sterility testing market is expected to reach USD 1.9 billion in 2028 from USD 1.1 billion in 2023 at a CARG of 10.5%. Factors such as expanding pharmaceutical & biotechnology production capacities, increasing development of novel biopharmaceutical products, and rising investments in life sciences research are expected to drive market growth. However, the growing adoption of single-use technology and stringent regulatory guidelines for product approval are expected to restrain market growth to a certain extent.
Prominent players operating in the biomarkers market are Charles River Laboratories, Inc. (US), Merck KGaA (Germany), bioMérieux SA (France), SGS SA (Switzerland), WuXi AppTec (China), Nelson Laboratories, LLC (US), Pacific BioLabs (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Samsung Biologics (South Korea). The study includes an in-depth competitive analysis of these key players in the modular data center market with their company profiles, recent developments, and key market strategies. The players in this market have embraced different strategies to expand their global presence and increase their market shares. New product launches and enhancements, partnerships, acquisitions, and collaborations have been the most dominating strategies adopted by the major players.
To know about the assumptions considered for the study download the pdf brochure
Charles River Laboratories (Us)
Charles River is one of the key players in the sterility testing market. It is a service and early-stage contract research organization (CRO). The company develops a diverse portfolio of discovery & safety assessment services by providing a suite of products and services to support its clients’ manufacturing activities. Charles River Laboratories focuses on expanding its service and product offerings in the sterility testing segment to strengthen its market position further. The company offers customized assays to address specific concerns and needs, ensuring an appropriate testing plan is designed for biological products. Fast Track Testing is also available to deliver urgently needed results quickly. JADE Biomedical (China) and Cognate BioServices (US) acquisitions have further strengthened the company’s portfolio and geographic presence in the market.
bioMérieux SA (FRANCE)
The company has a strong presence in alternative sterility testing methods and is projected to maintain its vanguard in this niche over the foreseeable future. The company is focusing on adopting inorganic growth strategies to maintain its position and enhance its market share. For instance, in May 2022, the company acquired Specific Diagnostics (US). With this acquisition, bioMérieux will improve its presence in antimicrobial resistance while expanding its market-leading position globally in clinical microbiology. The company has products such as BACT/ALERT AND SCANRDI are pioneers in the field of rapid microbiological methods for sterility testing. These products bring down the timeline for sterility testing to 4 hours. Traditional sterility testing takes 11-14 days to provide results.
Sterility Testing Market by Product (Kits & Reagents, Instrument, Services), Test (Membrane Filtration, Direct Inoculation), Application (Pharma, Biological Manufacturing, Medical Device Manufacturing), End User (Pharma, Biotech) - Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE